imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
bortezomib ever pharma 2,5 mg/ml injektionsvätska, lösning
ever valinject gmbh - bortezomib - injektionsvätska, lösning - 2,5 mg/ml - bortezomib 2,5 mg aktiv substans; mannitol hjälpämne
bortezomib ebewe 3,5 mg pulver till injektionsvätska, lösning
ebewe pharma ges.m.b.h.nfg.kg - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - bortezomib 3,5 mg aktiv substans; mannitol hjälpämne
bortezomib avansor 3,5 mg pulver till injektionsvätska, lösning
avansor pharma oy - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - mannitol hjälpämne; bortezomib 3,5 mg aktiv substans
bortezomib avansor 2,5 mg pulver till injektionsvätska, lösning
avansor pharma oy - bortezomib - pulver till injektionsvätska, lösning - 2,5 mg - bortezomib 2,5 mg aktiv substans; mannitol hjälpämne
erlotinib avansor 25 mg filmdragerad tablett
avansor pharma oy - erlotinibhydroklorid - filmdragerad tablett - 25 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; erlotinibhydroklorid 27,32 mg aktiv substans
erlotinib avansor 150 mg filmdragerad tablett
avansor pharma oy - erlotinibhydroklorid - filmdragerad tablett - 150 mg - erlotinibhydroklorid 163,94 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne
erlotinib avansor 100 mg filmdragerad tablett
avansor pharma oy - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,29 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
erlotinib orion 100 mg filmdragerad tablett
orion corporation - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,3 mg aktiv substans; laktos (vattenfri) hjälpämne